What is Leerink Partnrs' Forecast for ALDX Q1 Earnings?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Aldeyra Therapeutics in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the biotechnology company will earn ($0.27) per share for the quarter. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics' Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($0.45) EPS and FY2028 earnings at $0.75 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30).

ALDX has been the subject of several other reports. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, April 4th. BTIG Research reduced their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX traded up $0.13 on Wednesday, hitting $2.32. The stock had a trading volume of 633,087 shares, compared to its average volume of 702,648. Aldeyra Therapeutics has a 52-week low of $1.14 and a 52-week high of $7.20. The stock has a market cap of $138.52 million, a price-to-earnings ratio of -2.47 and a beta of 0.94. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The business's 50-day simple moving average is $5.16 and its two-hundred day simple moving average is $5.15.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC bought a new position in Aldeyra Therapeutics in the 4th quarter worth approximately $52,000. Balyasny Asset Management L.P. purchased a new position in Aldeyra Therapeutics during the fourth quarter valued at $56,000. Wealth Enhancement Advisory Services LLC bought a new stake in Aldeyra Therapeutics in the 1st quarter valued at $63,000. Catalyst Funds Management Pty Ltd lifted its stake in Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 12,500 shares in the last quarter. Finally, Regal Investment Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at about $66,000. Institutional investors own 59.71% of the company's stock.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.50% of the stock is owned by company insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.